Incyte Corporation (INCY) has recently garnered attention from Marc Frahm, an analyst at TD Cowen. In a report released yesterday, Frahm reaffirmed his "Buy" rating on the biopharmaceutical company, setting a price target of $88.00. This upbeat outlook comes as Incyte's shares closed...
DHS Launches Polygraph Tests toCombat Leaks of Immigration Raid Details
The Department of Homeland Security (DHS) has recently begun administering polygraph tests...
Recent research indicates a decline in confidence among aspiring homeowners in the UK, with a biannual study involving 1,000 participants revealing a notable shift...
In a positive turn of events, the British Retail Consortium (BRC)-NielsenIQ Shop Price Index has reported a sixth consecutive month of slowing shop price...